Research programme: anticancer therapeutics - Protarga/ICOS

Drug Profile

Research programme: anticancer therapeutics - Protarga/ICOS

Alternative Names: Anticancer therapeutics research programme - Protarga/ICOS

Latest Information Update: 19 Apr 2007

Price : $50

At a glance

  • Originator ICOS Corporation; Luitpold Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Apr 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly
  • 31 Oct 2003 Protarga has been acquired by Luitpold Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top